Anaphylaxis News and Research

RSS

Anaphylaxis is an acute multi-system severe type I hypersensitivity reaction. Due in part to the variety of definitions, between 1% and 15% of the population of the United States can be considered "at risk" for having an anaphylactic reaction if they are exposed to one or more allergens. Of those people who actually experience anaphylaxis, up to 1% may die as a result.

Amedra Pharmaceuticals re-launches single-dose epinephrine auto-injector, Adrenaclick

Amedra Pharmaceuticals LLC has announced re-launch of Adrenaclick®, a single-dose epinephrine auto-injector, for the emergency treatment of life threatening allergic reactions in people who are at risk for or have a history of anaphylaxis. Adrenaclick® will be available as a two-pack carton in both 0.15 mg and 0.30 mg strengths.

15 Jun 2013

Lineage Therapeutics announces US launch of generic epinephrine auto-injector

Lineage Therapeutics Inc. has announced the US launch of its generic epinephrine injection, USP auto-injector, the authorized generic of Adrenaclick by Amedra Pharmaceuticals LLC, for the emergency treatment of life-threatening allergic reactions in people who are at risk for or have a history of anaphylaxis.

15 Jun 2013

New Australian research shows evidence for pre-birth programming of food allergies

Among the many new findings presented at the EAACI-WAO World Allergy and Asthma Congress 2013 in Milan from 22-26 June 2013 is new Australian research providing proof for pre-birth programming of food allergies, showing that prenatal environmental factors may already determine predispositions for food allergies rather than only genetic factors.

7 Jun 2013

Ragweed allergy sublingual immunotherapy: an interview with Dr. Peter Creticos, Johns Hopkins University School of Medicine

Ragweed is a dominant seasonal allergen in North America (~26% of US and North American population is allergic to this noxious weed which pollinates from early August to early October).

31 May 2013

Research data on AMPYRA Extended Release Tablets to be presented at CMSC and ACTRIMS meeting

Acorda Therapeutics, Inc. will present new research data on AMPYRA (dalfampridine) Extended Release Tablets, 10 mg at the 5th Cooperative Meeting of the Consortium of Multiple Sclerosis Centers and Americas Committee for Treatment and Research in Multiple Sclerosis, being held in Orlando, FL, May 29 - June 1.

28 May 2013

Boehringer Ingelheim updates HCPs, patients on COMBIVENT RESPIMAT Inhalation Spray

As part of the company's commitment to chronic obstructive pulmonary disease patients, Boehringer Ingelheim Pharmaceuticals, Inc., a leader in respiratory health, is updating healthcare professionals and patients that the transition to COMBIVENT RESPIMAT (ipratropium bromide and albuterol) Inhalation Spray for the maintenance treatment of COPD is nearly complete.

18 May 2013

Merck, Pfizer sign collaboration agreement for development and commercialization of ertugliflozin

Merck & Co., Inc., known as MSD outside the United States and Canada, and Pfizer Inc. today announced that they have entered into a worldwide (except Japan) collaboration agreement for the development and commercialization of Pfizer's ertugliflozin (PF-04971729), an investigational oral sodium glucose cotransporter (SGLT2) inhibitor being evaluated for the treatment of type 2 diabetes.

From Pfizer, Inc. 30 Apr 2013

BD receives FDA approval for second prefilled injectable drug

BD Rx Inc., a wholly-owned subsidiary of leading global medical technology company BD, announced today that the U.S. Food and Drug Administration has approved the second drug to be offered in the recently launched BD Simplist line of ready-to-administer prefilled generic injectables.

From BD (Becton, Dickinson and Company) 24 Apr 2013

Acorda Therapeutics reports positive data from dalfampridine-ER post-stroke deficits trial

Acorda Therapeutics, Inc. today announced that a proof-of-concept trial found dalfampridine extended release tablets, marketed as AMPYRA (dalfampridine) Extended Release Tablets, 10 mg, improved walking in people with post-stroke deficits.

16 Apr 2013

Biogen acquires TYSABRI stake from Elan

Biogen Idec today announced it has completed its purchase of Elan Corporation's interest in TYSABRI (natalizumab) and has gained full strategic, commercial and decision-making rights to TYSABRI.

3 Apr 2013

Review article shows sublingual immunotherapy may be useful for allergic rhinitis, asthma

In an examination of a type of treatment for allergic rhinitis and asthma that is used in Europe but not approved by the U.S. Food and Drug Administration, researchers found moderate strength in the evidence from previous studies to support the use of sublingual immunotherapy for the treatment of these conditions, according to an article in the March 27 issue of JAMA.

27 Mar 2013

Passengers engaged in eight mitigating factors less likely to report allergic reaction, researchers find

Few situations can provoke more anxiety for people with peanut or tree-nut allergies than having an allergic reaction while flying on an airplane and being unable to get help.

16 Mar 2013

More than 60% of fire ant allergic patients do not adhere to treatment guidelines

Two million Americans are allergic to insect stings, an allergy which sends more than 500,000 people to the emergency room annually. Yet, according to a study published today in the March issue of Annals of Allergy, Asthma & Immunology, the scientific journal of the American College of Allergy, Asthma and Immunology (ACAA), while fire ant allergy sufferers know allergy shots can save their life, more than 60 percent do not adhere to treatment guidelines.

4 Mar 2013

Amoxicillin effectiveness: an interview with Prof Paul Little, University of Southampton

Amoxicillin is a broad spectrum penicillin, and in the UK is one of the most frequently used antibiotics. It is commonly used either on its own or, where there are particular concerns about resistance, in combination as Co-amoxiclav (as Amoxicillin-clavulanic acid) which extends its anti-bacterial spectrum.

1 Mar 2013

Otsuka receives FDA approval for ABILIFY MAINTENA to treat schizophrenia

Otsuka Pharmaceutical Co., Ltd. (Otsuka) and H. Lundbeck A/S (Lundbeck) announced the U.S. Food and Drug Administration (FDA) has approved ABILIFY MAINTENA (aripiprazole) for extended- release injectable suspension, an intramuscular (IM) depot formulation indicated for the treatment of schizophrenia.

1 Mar 2013

FDA alerts patients and health care providers of voluntary recall of Omontys by Affymax

The U.S. Food and Drug Administration is alerting health care providers and patients of a voluntary nationwide recall of all lots of Omontys Injection by Affymax, Inc., of Palo Alto, Calif., and Takeda Pharmaceuticals Company Limited, of Deerfield, Ill.

25 Feb 2013

rEVO Biologics announces results from Atryn phase 3 studies on pregnant AT-deficient women

rEVO Biologics announced today the results of a major retrospective study analysis of its pivotal phase 3 studies which demonstrate that pregnant patients with hereditary antithrombin deficiency (HD) benefit from ATryn Antithrombin (Recombinant) therapy to prevent venous thromboembolic events (VTE).

16 Feb 2013

Anaphylaxis News and Research

Further Reading